Gene expression from bronchoscopy obtained tumour samples as a predictor of outcome in advanced inoperable lung cancer

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Suwinski, Rafal ^a   Klusek, Artur ^b   Tyszkiewicz, Tomasz ^a   Kowalska, Maria ^a   Szczesniak Klusek, Bogna ^a   Gawkowska Suwinska, Marzena ^a   Tukiendorf, Andrzej ^a   Kozielski, Jerzy ^c   Jarzab, Michal ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b Department of Pulmonology   (Poland)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ADULT; ADVANCED CANCER; ARTICLE; BRONCHOSCOPY; CA9 GENE; CANCER PROGNOSIS; CANCER STAGING; CDKN1B GENE; CSF1 GENE; DIFFERENTIAL DIAGNOSIS; DUSP6 GENE; EGFR GENE; ERBB3 GENE; ERCC1 GENE; FEMALE; FN1 GENE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC MARKER; HUMAN; HUMAN TISSUE; INOPERABLE CANCER; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MMD GENE; ONCOGENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; QUANTITATIVE ANALYSIS; RADIODIAGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; STAT1 GENE;

ADULT; AGED; BRONCHOSCOPY; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; SURVIVAL RATE;

EID: 84864412866     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041379     Document Type: Article

References (18)

1. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, et al.((2007)) A five-gene signature and clinical outcome in non-small cell lung cancer. NEJM 356:: 11--20.
2. Skrzypski M, Jassem E, Taron M, Sanchez JJ, Mendez P, et al.((2008)) Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res 14:: 4794--4798.
3. Larsen JE, Pavey SJ, Passmore LH, Bowman R, Clarke BE, et al.((2007)) Expression profiling defines a recurrence signature in lung squamous cell carcinoma. Carcinogenesis 28:: 760--6.
4. Larsen JE, Pavey SJ, Passmore LH, Bowman RV, Hayward NK, et al.((2007)) Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res 13:: 2946--54.
5. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, et al.((2002)) Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8:: 816--24.
6. Subramanian J, Simon R,((2010)) Gene expression-based prognostic signatures In lung cancer: ready for clinical use? JNCI 102:: 464--74.
7. Inamura K, Fujiwara T, Hoshida Y, Isagawa T, Jones MH, et al.((2005)) Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and non-negative matrix factorization. Oncogene 24:: 7105--13.
8. Raponi M, Zhang Y, Yu J, Chen G, Lee G, et al.((2006)) Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 66:: 7466--72.
9. Baty F, Facompre M, Kaiser S, Schumacher M, Pless M, et al.((2010)) Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer. Am J Resp Crit Care Med 181:: 181--88.
10. MacQueen J (1967) Some methods for classification and analysis of multivariate observations. Proc. 5-th Berkeley Symposium on Mathematical Statistics and Probability, University of California Press, Berkeley. 281-297.
11. Cohen J,((1960)) A coefficient of agreement for nominal scales. Educational and Psychological Measurement 20:: 37--46.
12. Rosell R, Skrzypski M, Jassem E, Taron M, Bertolucci R, et al.((2007)) BRCA1: A novel prognostic factor In resected non-small cell lung cancer. PLoS ONE; 2:: e1129. Available: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001129. Accessed 2012 Apr 18.
13. Swinson DE, Jones JL, Richardson D, Wykoff C, Turtley H, et al.((2003)) Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 21:: 473--82.
14. Shapiro GI, Supko JG, Patterson A, Lynch C, Lucca J, et al.((2001)) A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 7:: 1590--1599.
15. Kawano O, Sasaki H, Endo K, Suzuki E, Haneda H, et al.((2008)) ErB3 mRNA expression correlated with specific clinicopathologic features of Japanese lung cancer J Surg Res. 146:: 43--8.
16. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, et al.((2006)) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med. 355:: 983--91.
17. Han S, Khuri FR, Roman J,((2006)) Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res 66:: 315--23.
18. Soria JC, Mok TS, Cappuzzo F, Janne PA (2011) EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects. Cancer Treat. In press.